A flock of ex-CSL executives drives new Paradigm

The huge focus on the race to find a coronavirus vaccine is likely to cause a rerating of biotech companies researching other medical problems, says the chief executive of Paradigm Biopharmaceuticals, which aims to become a big player in osteoarthritis treatments.

Paul Rennie said the spillover should be a benefit to a host of ASX groups, with Paradigm among them as investors reassess the potential commercial benefits of unlocking the answers to other pressing health issues.